Cidara Therapeutics
San Diego
About Cidara Therapeutics
Cidara Therapeutics develops targeted immunotherapies aimed at improving treatment outcomes for patients with serious diseases. The company utilizes its Cloudbreak platform to create single-molecule cocktails that combine small molecules and peptides with human antibody fragments. These drug-Fc conjugate immunotherapies are designed to target specific disease mechanisms while simultaneously activating the immune system. Cidara focuses on applications in infectious diseases, such as influenza, as well as in immuno-oncology. Its approach integrates molecular targeting with immune engagement to address challenging medical conditions. The company continues to advance its pipeline of therapies through research and development initiatives.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $1.3B
- Funding stage: M&A
- Last round: Grant (Oct 2025)
- Ticker: nasdaq:CDTX
- Website: cidara.com
- Phone: 858-230-8519
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/cidara-therapeutics-26100 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.